To determine if the neuroprotective effects of the FTO inhibitor on MN degeneration in ALS are mediated through its regulation of m6A-modified ALS risk genes (Fig. 6g, h), we performed RNA-seq analysis on ALS iPSC~MNs treated with FB23-2. This evidence concerns the gene FTO and amyotrophic lateral sclerosis.